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Abstract 
We report baseline results of a community-based, targeted, low dose CT (LDCT) lung cancer 
screening pilot in deprived areas of Manchester. Ever smokers, age 55-74, were invited to 
 ?>ƵŶŐ ,ĞĂůƚŚ ŚĞĐŬs ? ŶĞǆƚ ƚŽ ůŽĐĂů ƐŚŽƉƉŝŶŐ ĐĞŶƚƌĞƐ ?with immediate access to LDCT for 
those at high-risk (6-year risk A? ? ? ? ?A? ? W>KM2012 calculator). 75% of attendees 
(n=1893/2,541) were ranked in the lowest deprivation quintile; 56% were high-risk and of 
1,384 individuals screened 3% (95% CI 2.3-4.1%) had lung cancer (80% early stage) of whom 
65% had surgical resection. Taking lung cancer screening into communities, ǁŝƚŚ Ă  ?>ƵŶŐ
,ĞĂůƚŚŚĞĐŬ ?ĂƉƉƌŽĂĐŚ, is effective and engages populations in deprived areas.  
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Introduction 
The symptomatic presentation of lung cancer is typically associated with advanced disease 
and poor survival. Screening asymptomatic at risk subjects with low dose CT reduces lung 
cancer specific mortality by 20% (1). However, current smoking and low socio-economic 
status (SES) are associated with reduced participation in lung cancer screening trials (2-4). 
Reducing barriers to participation in those at greatest risk is a critical challenge to screening 
implementation (5). To address this and the high burden of lung cancer in our local 
community, we designed and piloted a community-based, lung cancer screening service. The 
screening programme was developed around the concept of a one-ƐƚŽƉ ?>ƵŶŐ,ĞĂůƚŚŚĞĐŬ ? ?
which incorporated a holistic lung health programme and was located next to local shopping 
centres. The service was designed to minimise barriers to participation by reducing travel 
and increasing convenience/service accessibility. We selected screening participants 
according to individualised risk, using the PLCOM2012 model, at a 6-year lung cancer risk 
ƚŚƌĞƐŚŽůĚŽĨA? ? ? ? ?% (6). A similar approach was used in the UK Lung Cancer Screening Trial 
(UKLS), which selected participants based on 5-year risk A? ?A? ?Liverpool Lung Project model), 
this was cost-effective and resulted in a high prevalence of lung cancer (7).  
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Methods 
Ever smokers, aged 55-74, registered at participating GP practices (n=14), were invited to a 
community-based  ?Lung Health Check ? (LHC), where respiratory symptoms, spirometry and 
6-year lung cancer risk (PLCOM2012) were assessed alongside smoking cessation advice (8); 
ĂŶǇŽŶĞ ǁŝƚŚ Ă ƌŝƐŬ A? ? ? ? ?A? was offered annual screening, over two screening rounds, 
including an immediate LDCT scan (see supplementary file for more detailed methodology). 
CT scans were reported by NHS Consultant Radiologists with an interest in thoracic 
radiology. Pulmonary nodules were managed in accordance with British Thoracic Society 
(BTS) guidelines adapted for an annual screening programme (9). Scan reports were 
categorised as negative, indeterminate or positive. Indeterminate results required a 3-
month surveillance scan and positives immediate assessment in the rapid access lung cancer 
clinic. A false positive was any screened individual referred to the cancer clinic who was not 
diagnosed with lung cancer.  
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Results  
Demand was extremely high and all LHC appointments were booked within a few days; 
99.5% consented to the research database (n=2,541). Baseline characteristics are detailed in 
Table 1. 56.2% (n=1,429) of attendees qualified for screening and 1,384 had a LDCT scan (35 
excluded because CT thorax <12 months, 7 declined and 3 unable - claustrophobia); 82.6% of 
baseline scans were classified negative (n=1,143), 12.7% indeterminate (n=176) and 4.7% 
positive (n=65) (Figure 1). Negative scans had no nodules (73.8%; n=844), nodules <6mm 
(24.9%; n=284) or larger stable/benign nodules (1.3%; n=15). Three-month scans were 
performed for either nodule (87.8%; n=166) or non-nodule surveillance (12.2%; n=23). The 
dominant nodule at baseline was solid (54.2%; n=90), part solid (12%; n=20) or a pure 
ground glass opacity (pGGO) (33.7%; n=56).  
 
Of 81 (5.9%) individuals assessed in the cancer clinic, 42 were confirmed to have lung cancer. 
The false positive rate was 48.1% (n=39/81) as a proportion of cancer clinic referrals, or 2.8% 
of everyone screened. Patients who ultimately did not have cancer had the following 
investigations: PET-CT (n=17), bronchoscopy (n=9), endobronchial ultrasound (n=3), staging 
CT (n=6) and percutaneous biopsy (n=4). No surgical interventions were required for benign 
disease; one patient had a pneumothorax post CT-guided biopsy.  
 
The prevalence of lung cancer was 3% (95% CI 2.3-4.1%; n=42/1,384); 46 lung cancers were 
detected as three patients had >1 cancer (Table 1). Cancers were 63% stage I (n=29/46), 
17.4% stage II (n=8/46), 8.7% stage III (n=4/46) and 10.9% stage IV (n=5/46). Whilst we 
recognise the inherent biases associated with historical controls, this represented a 
significant stage shift (p<0.0001) compared to lung cancers (n=399) diagnosed across the 
same geographic area the year before the pilot started (31% stage I+II, 48% stage IV). The 
characteristics of screen detected cancers are detailed in Table 2; pathological types 
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included adenocarcinoma (n=24), squamous cell (n=13), small cell (n=2), adeno-squamous 
(n=2) and carcinoid (n=1). Four cases had a clinical diagnosis without pathological 
confirmation. The surgical resection rate was 65.2% (n=30/46). There was one death within 
90 days of surgery. A curative intent treatment was offered for 89.1% (n=41/46) of cancers.  
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Discussion 
In this paper, we report baseline results from ƚŚĞ h< ?Ɛ ĨŝƌƐt community-based, LDCT lung 
cancer screening service, utilising mobile CT scanners. Our approach was to target high-risk 
individuals in deprived areas of Manchester, with an invitation to convenient community-
based  ?>ƵŶŐ ,ĞĂůƚŚ ŚĞĐŬs ? with immediate access to CT. We selected the screened 
population according to individual risk scores (PLCOM2012). The prevalence of lung cancer was 
3% and most screen detected lung cancers were early stage (80.4%). The surgical resection 
rate was 65%, four-fold higher than the UK average. Median deprivation rank was within the 
lowest decile for England (2,873), markedly lower than UKLS (17,374) (7) and in contrast to 
screening trials where participation favours more affluent and better educated individuals 
(2); suggesting our approach engaged individuals of lower SES from deprived areas, a key 
ĚĞŵŽŐƌĂƉŚŝĐŽĨƚŚĞ ?ŚĂƌĚ-to-ƌĞĂĐŚ ?. 
 
To minimise overdiagnosis only persistent pGGOs A? ?ŵŵ ǁĞƌĞsurveyed and sub-solid 
lesions ǁŝƚŚĂƐŽůŝĚĐŽŵƉŽŶĞŶƚA? ?ŵŵinvestigated; intervention was generally reserved for 
lesions with avidity on PET scan above the mediastinal blood pool or a volume doubling time 
<400 days. All surgŝĐĂůůǇ ƌĞƐĞĐƚĞĚ ĂĚĞŶŽĐĂƌĐŝŶŽŵĂƐ ŚĂĚ A? ? ?A? ŶŽŶ-lepidic and invasive 
histology, suggesting this approach was appropriate. No surgery was performed for benign 
disease. One death occurred within 90 days of surgery (in a patient with 2 confirmed lung 
cancers). This mortality is below the national average, but underlines the importance of 
appropriate patient selection and minimising unnecessary invasive procedures. 
 
In conclusion, our results have demonstrated that an appropriately designed service, using a 
 ?>ƵŶŐHĞĂůƚŚ ŚĞĐŬ ? approach, can engage participants at high risk of lung cancer from 
deprived areas. This resulted in high rates of early stage lung cancer detection with 
minimisation of harms. It was not a clinical trial but an evidence based pragmatic evaluation 
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of an NHS commissioned and implemented service within a regional lung cancer service. 
&ƵƌƚŚĞƌĞǀĂůƵĂƚŝŽŶŽĨƚŚĞDĂŶĐŚĞƐƚĞƌ ?>ƵŶŐ,ĞĂůƚŚŚĞĐŬ ?ŵŽĚĞůǁŝůůďĞƵŶĚĞƌƚĂŬĞŶŝŶĂƌŽůů
out of the service across the whole of North Manchester and at a number of additional sites 
as recently announced by NHS England (10). 
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was delivered by the lung cancer team at Wythenshawe Hospital, Manchester University 
NHS Foundation Trust, in partnership with Alliance Medical. LDCT reporting was performed 
by a consortium of NHS consultant radiologists with sub-speciality interest in thoracic 
medicine. The pilot service was commissioned by South Manchester Clinical Commissioning 
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Table 1. Characteristics of individuals who attended the LHC,  
stratified by lung cancer risk.  
 
Variable All 
Lung Cancer Risk 
p 
value 
High 
(PLCO t1.51%) 
Low 
(PLCO <1.51%) 
Number of attendees (%) 2,541 1,429 (56.2) 1,112 (43.8) - 
Mean age (years ±SD) 64.1 (5.5) 64.7 (5.4) 63.4 (5.5) * 
Sex M/F (F%) 1245/1296 (51.0) 706/723 (50.6) 539/573 (51.5) 0.64 
Median IMD rank (interquartile range) 2873 2866 (3994) 3109 (8345) * 
BMI 
(%) 
<18.5 42 (1.7) 33 (2.3) 9 (0.8) 
* 
18.5-24.9 531 (20.9) 353 (24.7) 178 (16.0) 
25-29.9 982 (38.7) 541 (37.9) 441 (39.7) 
30-39.9 875 (34.4) 460 (32.2) 415 (37.3) 
A? ? ? 111 (4.4) 42 (2.9) 69 (6.2) 
Education 
(%) 
>ĞƐƐƚŚĂŶ ?K ?ůĞǀĞů 1567 (61.7) 998 (69.8) 569 (51.2) 
* 
 ?K ?ůĞǀĞů 511 (20.1) 255 (17.9) 256 (23.0) 
 ? ?ůĞǀĞů 106 (4.2) 49 (3.4) 57 (5.1) 
University/college 213 (8.4) 84 (5.9) 129 (11.6) 
University degree 91 (3.6) 31 (2.2) 60 (5.4) 
Postgrad/professional 53 (2.1) 12 (0.8) 41 (3.7) 
Smoking status 
(%) 
Current 891 (35.1) 754 (52.8) 137 (12.3) 
* 
Former 1650 (64.9) 675 (47.2) 975 (87.7) 
Smoking exposure 
(mean ±SD) 
Duration (years) 34.6 (14.7) 43.8 (8.2) 22.8 (12.6) * 
Cigs / days 20.4 (13.0) 24.0 (12.9) 15.8 (11.5) * 
Packyears 36.7 (27.8) 51.6 (26.8) 17.7 (14.2) * 
Spirometry 
(mean ±SD) 
FEV1 2.3 (0.8) 2.1 (0.7) 2.6 (0.8) * 
% predicted FEV1 90.1 (25.0) 84.0 (24.3) 98.0 (23.6) * 
FVC 3.3 (1.0) 3.1 (1.0) 3.4 (1.0) * 
% predicted FVC 102.6 (24.9) 99.4 (24.5) 106.6 (24.7) * 
FEV1/FVC ratio 70.8 (10.6) 67.8 (11.0) 74.7 (8.7) * 
Airflow Obstruction Yes (%) 944 (37.2) 716 (50.1) 228 (20.5) * 
COPD/emphysema Yes (%) 566 (22.3) 471 (33.0) 95 (8.5) * 
FH Lung cancer Yes (%) 553 (21.8) 392 (27.4) 161 (14.5) * 
MRC Dyspnoea 
Score (%) 
1 1791 (70.5) 920 (64.4) 871 (78.3) 
* 
2 494 (19.4) 310 (21.7) 184 (16.6) 
3 163 (6.4) 123 (8.6) 40 (3.6) 
4 91 (3.6) 74 (5.2) 17 (1.5) 
5 2 (0.1) 2 (0.1) 0 (0)  
Performance Status 
(%) 
0 1552 (61.1) 768 (53.7) 784 (70.5) 
* 
1 763 (30.0) 481 (33.7) 282 (25.4) 
2 187 (7.4) 152 (10.6) 35 (3.1) 
3 38 (1.5) 28 (2.0) 10 (1.0) 
4 1 (0.0) 0 (0) 1 (0.0) 
(FH = Family History; IMD = Index of Multiple Deprivation; BMI = Body Mass Index) 
*p value < 0.0001 
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Table 2. Clinical details of screen detected lung cancers. 
(R) Radical treatment, (C) Concurrent treatment, (S) Sequential treatment,  
(P) Palliative treatment, (A) Adjuvant chemotherapy. A,B,C = cancers in the same patient 
*Case with a rapid development of a solid component over 3-months 
TNM staging using version 7 
ID Sex Age PS MRC TNM 
Final 
Stage 
Pathological type 
Histology sub-type 
(Resected Adenocarcinomas) 
Treatment 
1 M 57 1 1 cT1a N0 M0 IA Adenocarcinoma - Radiotherapy(R) 
2 F 61 2 3 pT1a N0 IA Adenocarcinoma Undetermined Surgery 
3 F 69 0 1 pT1a N0 IA Squamous - Surgery 
4 F 65 0 1 pT1a N0 IA Adenocarcinoma Acinar Surgery 
5 F 74 1 1 pT1a N0 IA Adenocarcinoma Acinar Surgery 
6 F 70 0 1 pT1b N0 IA Adenocarcinoma 
Lepidic 40%; Papillary 35%, 
Acinar 20%, Solid 5% 
Surgery 
7A 
F 60 3 4 
pT1a Nx IA Adenocarcinoma Acinar 
Surgery 8A pT1a Nx IA Adenocarcinoma Papillary 
9A pT1a Nx IA Adenocarcinoma Acinar 
10 F 74 2 4 cT1b N0 M0 IA Clinical - Surgery - Declined 
11 M 69 0 1 pT1a N0 IA Adenocarcinoma Papillary Surgery 
12 M 66 0 1 pT1a N0 IA Squamous - Surgery 
13 F 65 1 1 pT1a N0 IA Adenocarcinoma Lepidic 90%; Acinar 10%* Surgery 
14B 
F 74 1 1 
pT1a N0 IA Adeno-squamous Acinar 
Surgery 
15B pT1a N0 IA Squamous -  
16 F 72 2 1 pT1b N0 IA Typical Carcinoid -  Surgery 
17 M 73 0 1 pT1a N0 IA Adenocarcinoma Acinar Surgery 
18 M 64 1 1 cT1a N0 M0 IA Clinical -  SABR 
19 F 65 1 2 pT1a N0 IA Adenocarcinoma Acinar 80%, Lepidic 20% Surgery 
20 F 73 0 1 cT1a N0 M0 IA Clinical - Surgery - Declined 
21 F 72 0 2 pT1a N0 IA Squamous - Surgery 
22C 
F 73 1 1 
pT1aN0 IA Adenocarcinoma Acinar 70%, Lepidic 30% 
Surgery 
23C pT2aN0 IB Squamous - 
24 M 70 0 1 pT2a N0 IB Adenocarcinoma 
Mixed Acinar (>10%), Lepidic, 
Papillary 
Surgery 
25 F 71 0 1 pT2a N0 IB Squamous - Surgery 
26 M 67 1 3 pT2a N0 IB Adenocarcinoma 
Lepidic 55%, Papillary 40%, 
Acinar 5% 
Surgery 
27 F 64 1 4 pT2a N0 IB Adenocarcinoma Solid 90%, Acinar 10% Surgery 
28 F 67 1 3 pT2a N0 IB Adenocarcinoma Acinar 95%, Lepidic 5% Surgery 
29 F 62 3 4 cT2 N0 M0 IB Squamous - SABR 
30 F 60 0 1 cT1a N1 M0 IIA Small - Chemo-Radiotherapy(C) 
31 M 68 1 2 pT1a N1 IIA Adeno-squamous Solid Surgery/Chemotherapy(A) 
32 M 63 0 1 cT1 N1 M0 IIA Squamous - Radiotherapy(R) 
33 M 72 1 2 pT2b N0 IIA Adenocarcinoma Acinar Surgery 
34 M 69 3 5 cT1a N1 M0 IIA Small - Chemotherapy 
35 F 70 1 2 pT3 N0 IIB Adenocarcinoma 
Acinar 50%, Lepidic 40%, 
Papillary 10% 
Surgery 
36 M 73 0 1 cT3 N0 M0 IIB Squamous - Radiotherapy(R) 
37 M 57 3 5 cT3 N0 M0 IIB Clinical - Radiotherapy(R) 
38 F 61 0 1 pT2a N2 IIIA Squamous - Surgery/Chemotherapy(A) 
39 M 65 0 2 pT2a N2 IIIA Adenocarcinoma 
Acinar 60%, Lepidic 30%, 
Solid 5%, Papillary 5% 
Surgery/Chemotherapy(A) 
40 M 74 0 1 cT4 N2 M0 IIIA Squamous - Chemo-Radiotherapy(S) 
41 M 73 0 1 pT4 N2 IIIB Squamous - Surgery/Chemotherapy(A) 
42 F 65 2 3 cT4 N0 M1a IV Adenocarcinoma - Chemotherapy 
43 F 66 1 1 cT4 N2 M1b IV Adenocarcinoma - Radiotherapy(P) 
44 M 63 0 1 cT4 N2 M1b IV Squamous - Chemotherapy - Declined 
45 F 71 0 1 cT2 N2 M1b IV Adenocarcinoma - Chemo-Radiotherapy(S) 
46 M 71 2 4 cT4 N1 M1b IV Adenocarcinoma - Chemotherapy 
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Figure Legend 
 
 
Figure 1. Diagram showing flow of participants through the screening service. 
 
(LHC = lung health check; LDCT = low dose CT scan; 
* = based on GP recorded smoking status for 15,072 invitees). 
 
